创新药ETF国泰（517110）涨超3.2%；生物医药ETF（512290）涨超2.2%；医疗ETF（159828）涨超1.3%；疫苗ETF（159643）涨超1.0%，创新药与CXO板块获政策业绩双支撑

Core Viewpoint - The pharmaceutical and biotechnology sectors have seen significant gains recently, driven by supportive policies and strong performance from leading CXO companies, indicating a potential turning point for the sector's earnings [1] Group 1: ETF Performance - The Innovation Drug ETF (517110) rose over 3.2%, the Biopharmaceutical ETF (512290) increased by more than 2.2%, the Medical ETF (159828) gained over 1.3%, and the Vaccine ETF (159643) saw an increase of over 1.0% [1] - The Innovation Drug ETF tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in the research and production of innovative drugs, reflecting the overall performance of companies with research capabilities and growth potential [1] Group 2: Policy and Market Trends - Recent policies, including measures to support the high-quality development of innovative drugs and the 11th batch of centralized procurement notifications, are significant for the pharmaceutical and medical device sectors [1] - The performance of leading CXO companies that have disclosed their earnings has shown a recovery trend, suggesting that the earnings turning point for the sector may be approaching [1] Group 3: Index Descriptions - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which includes companies in biotechnology, pharmaceuticals, and medical devices, focusing on high-growth and strong R&D capabilities [2] - The Medical ETF (159828) follows the CSI Medical Index (399989), which represents companies in medical devices, services, and biopharmaceuticals, serving as an important benchmark for investment value in the domestic medical industry [2] - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), focusing on companies involved in vaccine research, production, and related industries, highlighting significant growth and specialization [2]